Singapore, June 9 -- A research team led by Dr Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in collaboration with Shine-On Biomedical Co., has developed the world's first targeted exosome drug delivery platform aimed at HLA-G (Human leukocyte antigen G), marking a major milestone in the field of precision oncology.

The novel platform, named SOB100, has completed preclinical studies and demonstrated promising efficacy in treating aggressive cancers such as breast cancer and glioblastoma.

The platform has received approval from the US Food and Drug Administration (FDA) to begin Phase I clinical trials in humans.

While HLA-G is typically restricted to placental tissue, many tumours exploit this mechanism to ...